Joint Statement on Donation of CV-19 Vaccines to African Countries

By donating the doses we have learned from our common experience, we want to attract the attention of the international community by enhancing the lessons learned over the past several months by the African Immunization Trust (AVAT), the African Center for Disease Control and Prevention (Africa CDC) and COVAX. Funding for Covad-19 Vaccines in Africa and other participating COVAX economies are particularly supported by Gawi COVAX Pre-Market Commitment (AMC).

AVAT and COVAX will strengthen each other’s efforts to support the integration of African countries Vaccination targets, 70% of Africans realize the global goal of immunization. Dos donations are an important source of supply and other sources are increasing, but donor quality needs to improve.

AVAT and COVAX focus on access to and release of CV-19 vaccines in Africa. Together, we are rapidly expanding our supply to the continent, and we are supporting countries to take advantage of what they receive. So far, more than 90 million doses have been delivered through COVAX and AVAT and millions more through bilateral events.

However, most of the donations are currently temporary, with little notice and a short waiting period. This has made it extremely difficult for countries to plan immunization campaigns and increase absorption capacity. This trend must be reversed in order to achieve higher coverage levels on the continent and to be a sustainable source of supply from AVAT and COVAX procurement agreements.

Countries need predictable and reliable supply. Short-term planning and short-term shelf life will greatly increase the logistical burden on existing health systems. In addition, this kind of temporary supply uses manpower, infrastructure, and cold chain – long-term successful and sustainable emissions. Also, short-acting doses increase the risk of dehydration after importation, which can have long-term consequences for the vaccine.

Donations to COVAX, AVAT and other African countries should be provided in a way that maximizes the coverage of efficient resource mobilization and long-term planning to support the release of countries. As of January 1, 2022, we call on the international community, particularly donors and manufacturers, to adhere to the following steps.

• Quantity and prediction; Donors should try to reduce the amount of donations made in large quantities and in a predictable way to reduce transaction costs. We acknowledge the progress being made in this area, but note that this frequency will increase the burden on countries, AVAT and COVAX.
• Shortening These quantities must be unarmed to support maximum effectiveness and long-term planning. Earmarking makes it very difficult to allocate equity-based supply and take into account the absorption capacity of certain countries. Short-term donations also increase the risk of developing countries’ cold chain capacity – capacity then AVAT or COVAX is not available when long shelf life rates are set by their own purchase agreement.
• Shelf life; By default, disposable doses must have a shelf life of at least 10 weeks upon import, with the exception of certain exceptions, indicating the desire and ability to drink with a short shelf life.
• Previous ad Recipient countries must notify you of any donations in less than 4 weeks before entering the country.
• Response times emer- All stakeholders need to be quick to respond to important information. This includes important supply information from manufacturers (donation total volumes, shelf life, production location), donation confirmation from donors and acceptance of donations from countries. Last-minute information further complicates processes, increases transaction costs, reduces shelf life, and increases risk of termination.
• Assistant Most donations so far do not include essential immunization supplies such as syringes and supplements and do not cover shipping costs – which means these should be provided separately – for additional costs, complexity and delay. Donations should be made with all necessary auxiliary components to ensure fast placement and absorption.

As we continue to work together to achieve Africa’s immunization goals, EVAT, Africa CDC and CVX are committed to partnering with donor countries, vaccine manufacturers and partners.

______________________________________________________________________________

Notes for editors

About the African Union

The 55 member states of the African Union (AU) have joined the African Union (AU). It was officially launched in 2002 as the successor to the Organization of African Unity (OAU, 1963-1999). https://au.int/en/overview

About Africa CDC

The African Center for Disease Control and Prevention (Africa CDC) is a specialized technical institution of the African Union, which strengthens the capacity of African public health facilities and strengthens partnerships to respond quickly and effectively to disease threats and epidemics. On data-supported interventions and programs. Learn more by searching www.africacdc.org

About the African Immunization Trust (AVAT)

The African Immunization Trust (AVAT) is a special purpose vehicle built in Mauritius. AVAT, acting as a central procurement agent on behalf of African Union member states, works to ensure that at least 70% of the African population is vaccinated to achieve the required Covide-19 immunization strategy to protect the necessary vaccines and integrated funding sources. The whole of Africa. Avat was established by the Covide-19 African Vaccination Team. In November 2020, President Cyril Ramaphosa was inaugurated as the President of the African Union. August 2020 supports the Covide-19 Vaccine Strategy approved by the Office of the Heads of State and Government of the African Union. EVAT’s main partners are the African Union Center for Disease Control and Prevention (Africa CDC), the African Export-Import Bank (Afreximbank), and the United Nations Economic Commission for Africa (ECA).

About COVAX

COVAX, Vaccine Pillar Immediate access to Covid-19 devices (ACT)In collaboration with CEPI, Gavi, and the World Health Organization – UNICEF and PAHO, we are working together as delivery partners, vaccine manufacturers in developed and developing countries, the World Bank and others. Covide-19 vaccines are the only international initiative working with governments and manufacturers to ensure that high-income and low-income countries are available globally.